New AD in Sephardi Jews Study Launches

A new study funded by a grant of more than $13 million from the US National Institutes of Health will look into possible genetic reasons why Sephardic Jews are diagnosed with Alzheimer’s disease at younger ages than other people.

The project officially launched on May 5 as representatives of partner institutions met at Beilinson Hospital in Petah Tikva. Aside from Beilinson, the research consortium includes Rambam Medical Center in Haifa, Barzilai Medical Center in Ashkelon, Laniado Hospital in Netanya, and Prof. Lindsay A. Farrer from Boston University School of Medicine.

A kick-off meeting on May 5, 2024 for a five-hospital collaboration for an NIH-funded Alzheimer’s study is attended by: Beilinson Hospital Director of Cognitive Neurology Dr. Amir Glik; Prof. Lindsay Farrer, Director, Boston University Molecular Genetics Core Facility, Boston University School of Medicine; Rambam Health Care Campus Director of Cognitive Neurology Dr. Rachel Ben Hayun; Barzilai Medical Center Director of Cognitive Neurology Dr. Zeev Nitsan; and Prof. Bowirrat Abdalla, Senior Neurologist at Laniado hospital. (Courtesy of Beilinson Hospital)


This new research builds on a peer-reviewed study conducted at Beilinson and published in 2018 in the Journal of Alzheimer’s Disease. It showed a disparity between the prevalence of early-onset Alzheimer’s disease (EOAD) in Sephardi versus Ashkenazi Jews.

Read the full news article here.